TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7104157

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30958026

Group type: EXPERIMENTAL
Intervention: Signal-contingent recording
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Event-contingent recording
Number of subjects: 286
Study: 29928989

Group type: EXPERIMENTAL
Intervention: Risk score for veno-occlusive disease (VOD)
Number of subjects: 13097

Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning regimens
Number of subjects: 13097

Group type: EXPERIMENTAL
Intervention: Busulfan-based myeloablative conditioning regimens guided by pharmacokinetic monitoring
Number of subjects: 13097

Group type: EXPERIMENTAL
Intervention: Pretransplant risk score
Number of subjects: 13097
Study: 27834446

Group type: EXPERIMENTAL
Intervention: CVVH-HCO
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVVH-Std
Number of subjects: 0
Study: 24623502

Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaseline gauze care
Number of subjects: 50
Study: 23158128

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 1 µg/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 2 µg/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 3 µg/ml
Number of subjects: 120
Study: 20631056

Group type: EXPERIMENTAL
Intervention: Patient education booklet and BP tracker
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard approach of hypertension information leaflet
Number of subjects: 109
Study: 17196293

Group type: EXPERIMENTAL
Intervention: peginterferon/ribavirin therapy
Number of subjects: 1144
Study: 15734599

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12472620

Group type: EXPERIMENTAL
Intervention: Maca Gelatinizada 1,500 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maca Gelatinizada 3,000 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9696953

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 6 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily for 6 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Furosemide 20 mg intravenously)
Number of subjects: 8
Study: 7864501

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 20
Study: 2684076

Group type: EXPERIMENTAL
Intervention: Intramuscular LEFAC (bovine liver extract containing folic acid and cyanocobalamin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31135817

Group type: EXPERIMENTAL
Intervention: Galcanezumab, 120 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Galcanezumab, 240 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 29098381

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500-mg administered orally once daily on study days 4 through 11
Number of subjects: 24
Study: 26239482

Group type: EXPERIMENTAL
Intervention: Caffeine and albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 0
Study: 23426660

Group type: EXPERIMENTAL
Intervention: Training in the morning followed by a night of sleep
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training in the evening followed by a night of sleep
Number of subjects: 32
Study: 21282539

Group type: EXPERIMENTAL
Intervention: Carboplatin (one infusion at 7 × (glomerular filtration rate + 25) based on EDTA)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Carboplatin (at least 99% of the 7 × AUC dose)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Carboplatin (lower doses)
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 1447
Study: 20137694

Group type: EXPERIMENTAL
Intervention: 52-week rabeprazole treatment
Number of subjects: 98
Study: 16944825

Group type: EXPERIMENTAL
Intervention: Customized exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Customized and Standard)
Number of subjects: 30
Study: 15210659

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 18

Group type: COMPARATOR
Intervention: No Theophylline (Control)
Number of subjects: 18
Study: 11259888

Group type: EXPERIMENTAL
Intervention: 50 mg potassium diclofenac orally 1 hour preoperatively and placebo 30 minutes postoperatively (Preop group)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 25 mg potassium diclofenac 1 hour preoperatively and 25 mg diclofenac 30 minutes postoperatively (Pre+postop group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo 1 hour preoperatively and 50 mg potassium diclofenac 30 minutes postoperatively (Postop group)
Number of subjects: 127
Study: 9140151

Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (UBT) with 75 mg 13C-urea and citric acid
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (UBT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Non-fasting conditions
Number of subjects: 77
Study: 8315437

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg to 2 mg per day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 3802713

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: E-10-hydroxynortriptyline (E-10-OH-NT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29150957

Group type: EXPERIMENTAL
Intervention: Xenogeneic bone block loaded with rhBMP‐2 (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone block (control)
Number of subjects: 24
Study: 27754881

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T algorithm
Number of subjects: 2222

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I algorithm
Number of subjects: 2222
Study: 25301763

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 22980158

Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of four educational sessions over 4 consecutive weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional education method (Control group)
Number of subjects: 200
Study: 20151824

Group type: EXPERIMENTAL
Intervention: T4‐WD Group (levothyroxine withdrawal for 4 weeks)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: T3‐WD Group (levothyroxine withdrawal for 4 weeks plus 2 weeks on and then 2 weeks off liothyronine)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: rhTSH Group (recombinant human thyroid-stimulating hormone administration)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: rhTSH Group
Number of subjects: 291

Group type: COMPARATOR
Intervention: T4‐WD Group
Number of subjects: 291

Group type: COMPARATOR
Intervention: T3‐WD Group
Number of subjects: 291
Study: 18292586

Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells pulsed with two MAGE‐A3 antigenic peptides (HLA‐A1 and HLA‐DP4)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells pulsed with two MAGE‐A3 antigenic peptides
Number of subjects: 2
Study: 15795446

Group type: EXPERIMENTAL
Intervention: Daily iron treatment (125 mg FeSO(4) plus ascorbate and folate)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Placebo (25 mg ascorbic acid and 10 microg folate)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonanemic controls
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Anemic mothers (both treatment and placebo)
Number of subjects: 81
Study: 12716806

Group type: EXPERIMENTAL
Intervention: Action stages (healthy eating intervention)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Contemplation stage (healthy eating intervention)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Precontemplators (healthy eating intervention)
Number of subjects: 768
Study: 10378240

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 67
Study: 8649493

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 560

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 560
Study: 1906433

Group type: EXPERIMENTAL
Intervention: Blacil preparation (20 mg disodium cromoglycate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lomudal preparation (20 mg disodium cromoglycate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both preparations (Blacil and Lomudal)
Number of subjects: 16
Study: 6357208

Group type: EXPERIMENTAL
Intervention: suprofen 200 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: suprofen 400 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: diflunisal 750 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study: 31311060

Group type: EXPERIMENTAL
Intervention: Join the Healthy Boat intervention
Number of subjects: 1739
Study: 31825026

Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied every 3 months
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied every 6 months
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 157
Study: 27823821

Group type: EXPERIMENTAL
Intervention: Single fraction of 19Gy
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Two fractions of 13.5Gy
Number of subjects: 170
Study: 25733083

Group type: EXPERIMENTAL
Intervention: Guided Imagery CD for 18 min
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 23640612

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Brinzolamide monotherapy
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Brimonidine monotherapy
Number of subjects: 1350
Study: 21561700

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg per day for patients below 50 kg and 100 mg per day for patients over 50 kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 150
Study: 19139220

Group type: EXPERIMENTAL
Intervention: Videophone intervention
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All interventions (videophone and telephone)
Number of subjects: 148
Study: 17196519

Group type: EXPERIMENTAL
Intervention: Plant sterols combined with exercise
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 16123091

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 50
Study: 12192663

Group type: EXPERIMENTAL
Intervention: HIV patients on anti-viral medication
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (unaffected matched controls)
Number of subjects: 14
Study: 10206449

Group type: EXPERIMENTAL
Intervention: GHRP-6 (90 microg i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GHRP-6 + GHRH
Number of subjects: 21
Study: 7551660

Group type: EXPERIMENTAL
Intervention: Methotrexate alone (MTX), n = 12
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methotrexate + Sulphasalazine (MTX + SASP), n = 14
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 2192197

Group type: EXPERIMENTAL
Intervention: Continuous 72 hour infusion (CI) of Adriamycin, 60 mg/m2 every 3 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravenous bolus (B) of Adriamycin, 60 mg/m2 every 3 weeks
Number of subjects: 47
Study: 715133

Group type: EXPERIMENTAL
Intervention: Feedback group (attempted to increase and decrease heart rate with visual display)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No-feedback group (attempted to increase and decrease heart rate without visual display)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tracking group (merely tracked a visual analog display of heart rate)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High cold‐pressor reactors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low cold‐pressor reactors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coronary-prone personality characteristics (measured by Jenkins Activity Scale)
Number of subjects: 30
Study: 31129369

Group type: EXPERIMENTAL
Intervention: Weight loss smartphone app (APP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: App plus weekly coaching (APP + C)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non-responders re-randomized to step-up treatment
Number of subjects: 400
Study: 28167311

Group type: EXPERIMENTAL
Intervention: Simulation training program (including pre-study e-learning and simulation)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Simulation training program
Number of subjects: 81
Study: 24905489

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 64
Study: 23490041

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel load
Number of subjects: 156

Group type: COMPARATOR
Intervention: 300 mg clopidogrel load
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Atorvastatin reload (80 mg + 40 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: No statin reload
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel load (secondary endpoint)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 300 mg clopidogrel load (secondary endpoint)
Number of subjects: 156
Study: 22117691

Group type: EXPERIMENTAL
Intervention: Home-based exercise and support programme
Number of subjects: 156

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 156
Study: 19220558

Group type: EXPERIMENTAL
Intervention: Brain plasticity-based computerized cognitive training program
Number of subjects: 487

Group type: COMPARATOR
Intervention: General cognitive stimulation program (active control)
Number of subjects: 487
Study: 17613274

Group type: EXPERIMENTAL
Intervention: Combination tablets (600mg calcium + 300mg magnesium + 100IU vitamin D3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets (1000mg calcium)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 15
Study: 15491318

Group type: EXPERIMENTAL
Intervention: Sonicare Elite
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sonicare Advance
Number of subjects: 45
Study: 11479391

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2 mg/kg) + L-Dopa (2 mg/kg per h)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2 mg/kg)
Number of subjects: 5
Study: 9758296

Group type: EXPERIMENTAL
Intervention: Reinsertion of the stylet before needle removal
Number of subjects: 600

Group type: COMPARATOR
Intervention: No reinsertion of the stylet before needle removal
Number of subjects: 600
Study: 7922005

Group type: EXPERIMENTAL
Intervention: Automated enumeration method for CD34+ cells using a two-tube assay and dedicated software.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control reagent combination using IgG1 control antibody labeled with PE.
Number of subjects: 0
Study: 2974252

Group type: EXPERIMENTAL
Intervention: Low-dose human [Ser-Tyr28]ANH infusion (1.1 pmol.kg-1.min-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-salt diet (HS)
Number of subjects: 8
Study: 5071698

Group type: EXPERIMENTAL
Intervention: Amylobarbitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent review by the doctor after the first prescription and cautionary advice to the patient
Number of subjects: 0
Study: 31292734

Group type: EXPERIMENTAL
Intervention: Real rTMS with cognitive training (CT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS with cognitive training (CT)
Number of subjects: 30
Study: 28537898

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg twice daily)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 25475435

Group type: EXPERIMENTAL
Intervention: Whey protein (0.6 g/kg fat-free mass; n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Leucine (matched amount to whey protein; n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no amino acid ingestion)
Number of subjects: 22
Study: 23584840

Group type: EXPERIMENTAL
Intervention: Individually adapted exercises and examination‐based physiotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Individually adapted exercises only (Control)
Number of subjects: 90
Study: 21531236

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 154
Study: 18751703

Group type: EXPERIMENTAL
Intervention: Tourniquet use during operation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tourniquet use during operation
Number of subjects: 80
Study: 16776703

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in migraineurs with aura (MA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in migraineurs without aura (MoA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) in control subjects
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of PT variability between migraineurs and controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phosphene thresholds (PTs) in migraineurs
Number of subjects: 25
Study: 14531592

Group type: EXPERIMENTAL
Intervention: StarBrite (35% hydrogen peroxide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opalescence Xtra Boost (38% hydrogen peroxide)
Number of subjects: 0
Study: 10750206

Group type: EXPERIMENTAL
Intervention: Supplementary patient-held record
Number of subjects: 650

Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 650
Study: 9082588

Group type: EXPERIMENTAL
Intervention: MT+tactivin (T)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Methotrexate (MT)
Number of subjects: 127
Study: 1422715

Group type: EXPERIMENTAL
Intervention: Bioptycut 14-G (B14)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tru-Cut 14-G (T14)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Bioptycut 18-G (B18)
Number of subjects: 151
Study: 6094194

Group type: EXPERIMENTAL
Intervention: Bromocriptin (2.5 mg, twice daily for 4 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study: 31514988

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (65% nitrous oxide/oxygen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxygen (control group)
Number of subjects: 60
Study: 30213173

Group type: EXPERIMENTAL
Intervention: Preoperative parecoxib administration (40 mg before skin incision and at 12 and 24 hours after the first dose)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Postoperative parecoxib administration (40 mg at wound closure and at 12 and 24 hours after the first dose)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no parecoxib administration)
Number of subjects: 127
Study: 27250001

Group type: EXPERIMENTAL
Intervention: CEFci arm (5‐Fu 200 mg/m(2) daily by 24‐h continuous infusion and epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenous bolus on day 1)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: CEF arm (cyclophosphamide 600 mg/m(2), epirubicin 100 mg/m(2), and 5‐Fu 600 mg/m(2) i.v. on day 1)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: EC arm (epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: CEFci arm
Number of subjects: 501

Group type: COMPARATOR
Intervention: CEF arm
Number of subjects: 501

Group type: COMPARATOR
Intervention: EC arm
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 501
Study: 24329966

Group type: EXPERIMENTAL
Intervention: Replacement of existing gas stove with electric stove
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placement of air purifiers with HEPA and carbon filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Installation of ventilation hood over existing gas stove
Number of subjects: 0
Study: 21777294

Group type: EXPERIMENTAL
Intervention: 20% water restriction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40% water restriction
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0% water restriction (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Water restriction (general)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Water restriction (local group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Water restriction (commercial group)
Number of subjects: 90
Study: 20925999

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation device (PFNA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 106
Study: 18588849

Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resectoscopy
Number of subjects: 60
Study: 11441423

Group type: EXPERIMENTAL
Intervention: Ecopipam 10 mg p.o.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ecopipam 25 mg p.o.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ecopipam 100 mg p.o.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cocaine 25 mg/70 kg i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cocaine 50 mg/70 kg i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ecopipam (all doses)
Number of subjects: 10